Jacobs Levy Equity Management
AXDX icon

Jacobs Levy Equity Management’s Accelerate Diagnostics AXDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,308
Closed -$23.4K – 961
2022
Q4 		$23.4K Sell
3,308
-7,390
-69% -$80.7K ﹤0.01% 933
2022
Q3 		$163K Buy
+10,698
New +$177K ﹤0.01% 946

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Jacobs Levy Equity Management's AXDX Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 3,308 shares — an estimated $23.4K sold.

Jacobs Levy Equity Management first reported a position in AXDX in Q3 2022 and held it in 2 quarters. The position peaked at $163K in Q3 2022. 67 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Jacobs Levy Equity Management reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,308 Accelerate Diagnostics shares in Q1 2023, an estimated $23.4K.
  • Jacobs Levy Equity Management first reported a position in Accelerate Diagnostics in Q3 2022 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Accelerate Diagnostics position peaked at $163K in Q3 2022.
  • 67 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.